Pangea Wellness Inc.

Pangea Wellness Inc.

PNGAF
Pangea Wellness Inc.US flagOther OTC
0.36
USD
+0.00
- -
5.44MMarket Cap
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
0.13
0.05
- -
- -
- -
Basic EPS, GAAP
- -
-0.25
-0.29
-0.15
-0.21
-0.1
Free Cash Flow per Basic Share
- -
-0.16
-0.17
-0.07
-0.11
-0.08
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
-0.11
-0.2
-0.23
-0.01
0.19
Tangible Book Value per Share
- -
0.05
-0.02
-0.08
0.04
-0.03
Basic Weighted Avg Shares
- -
5
6
7
22
11
Sales/Revenue/Turnover
- -
1
- -
- -
- -
- -
Operating Margin (%)
- -
-154.78
-564.3
-7,545.54
-4,529.94
-89,596.57
Depreciation Expense
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
-1
-2
-1
-5
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-194.13
-581.35
-8,450.19
-9,104.28
-98,687.41
Working Capital
1
- -
- -
-1
1
- -
LT Debt
- -
- -
- -
- -
- -
- -
Total Equity
1
- -
- -
-1
1
3
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Oct'24
Jan'25
Apr'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
8
28
Market Capitalization
- -
1
2

Working Capital

FRC

in mil. unless spec.
Oct'24
Jan'25
Apr'25
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-268.9%
Free Cash Flow
- -
- -
431.14%
Net Income, GAAP
- -
- -
339.01%
Sales/Revenue/Turnover
- -
- -
307.47%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.03
-0.04
-0.01
- -
-0.15
2025
-0.03
-0.02
- -
- -
-0.21
2026
-0.03
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Pratapvir Sandhu
Full Time Employees
2
Sector
Consumer Defensive
Industry
Packaged Foods
Address
8035-130th Street Surrey BC Canada V3W 0H7
IPO Date
Aug 25, 2022
Business
Pangea Natural Foods Inc. (PNGAF) manufactures and distributes plant-based food products and innovative wellness solutions focused on clean-label nutrition and non-injectable peptide therapies in North America. The company offers plant-based patties; old fashioned ghee made from grass-fed organic New Zealand butter; energy gel with apple-based honey for rapid nutrient delivery; vitality, sunshine, and greens blends; plant-based recovery drinks; munchie mix; and co-packing, manufacturing, supply-chain, and distribution services for third-party food and beverage companies; through its subsidiary Amino Innovations Corp., it provides peptide therapies including BPC for rapid muscle and joint recovery, and products targeting stress management, gut health, longevity, hair health, skin repair, sleep health, and immune support via oral and topical delivery systems. Products reach consumers through company websites, over 500 retail outlets across Canada and the United States such as Loblaws, Sobeys, Whole Foods, Save-On-Foods, Choices Markets, and select Air Canada and WestJet flights, as well as wholesale networks. Founded in 2021 and headquartered in Vancouver, British Columbia, Canada, with operations in Surrey, British Columbia, the company serves the packaged foods and consumer wellness sectors targeting health-conscious individuals and growing food brands. In Q2 2025, Pangea completed the acquisition of Amino Innovations Corp. to expand into peptide-based wellness products and needle-less delivery systems; it secured CAD 500,000 in development capital through a private placement in January 2025 and anticipates receiving CAD 2.9 million in additional funding; earlier in 2024, it launched co-packing services for scalability and cost savings while opting not to acquire Glory Juice Co. to prioritize core brand expansion.

Company News

APIChat
  • The Precision Peptide Company Inc. Signs Agreement with U.S.-Based 503A Sterile Compounding Pharmacy - Peptides to be 100% Compounded in the United States

  • The Precision Peptide Company to Exhibit as the Only Peptide Company at Dave Asprey's BEYOND Conference in Austin, Texas

  • The Precision Peptide Company Inc. Places Order for 20,000 BPC-157 Transdermal Patches

  • The Precision Peptide Company (BPC) Expands on Exclusive 50/50 Revenue Share Peptide Partnership with MMA.INC (MMA)

  • The Precision Peptide Company (BPC) Lead Product Achieves 95.5% Purity in Independent Lab Testing, Clearing the Industry Benchmark and Advancing Toward Commercial Launch

  • The Precision Peptide Company's Chief Scientific Officer Justin Kirkland to Be Featured on The Human Upgrade with Dave Asprey

  • The Precision Peptide Company Inc. Announces Exclusive Strategic Marketing Partnership with Mixed Martial Arts Group Limited

  • The Precision Peptide Company Nears Commercial Launch of Needle-Free BPC-157 Patch as Final Testing Advances

  • C$1.3 Million in Proceeds Received by The Precision Peptide Company from Warrant Exercises

  • The Precision Peptide Company Grants RSUs and Stock Options and Settles Debt

  • The Precision Peptide Company Announces Strategic Product Marketing Agreement

  • The Precision Peptide Company Applauds FDA Action Advancing Regulatory Clarity for Peptide Therapies

  • The Precision Peptide Company Announces Public Relations and Consulting Services Agreement

  • The Precision Peptide Company Launches New Corporate Website and Comments on Evolving U.S. Policy in Support of Peptide-Based Therapies

  • Pangea Announces Name Change

  • Pangea Announces Proposed Name Change

  • Amino Innovations Appoints Dave Asprey, Jim Gunning, and Travis Rosbach as Strategic Advisors to Support Brand Growth and Market Expansion

  • Amino Innovations Launches Wholesale Program to Bring Human Peptide Science to Clinics, Retailers., and Wellness Centers Nationwide

  • Pangea Announces Filing of Amended and Restated Interim Financial Statements and Management's Discussion and Analysis

  • Pangea Announces Name Change